Negative association of time in range and urinary albumin excretion rate in patients with type 2 diabetes mellitus: a retrospective study of inpatients

被引:4
作者
Chai, Sanbao [1 ]
Wu, Shanshan [2 ]
Xin, Sixu [1 ]
Yuan, Ning [1 ]
Sun, Jianbin [1 ]
Zhang, Xiaomei [1 ]
Ji, Linong [1 ,3 ]
机构
[1] Peking Univ Int Hosp, Dept Endocrinol & Metab, Beijing 102206, Peoples R China
[2] Capital Med Univ, Natl Clin Res Ctr Digest Dis, Beijing Friendship Hosp, Beijing 100050, Peoples R China
[3] Peking Univ Peoples Hosp, Dept Endocrinol & Metab, Beijing 100044, Peoples R China
关键词
Time in range; Type; 2; diabetes; Urinary albumin excretion rate; Blood glucose; CHRONIC KIDNEY-DISEASE; ALL-CAUSE; MORTALITY; HBA(1C); ADULTS;
D O I
10.1097/CM9.0000000000001914
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Time in range (TIR) refers to the time an individual spends within their target glucose range, which now has been popularized as an important metric to classify glycemic management and also recognized as an important outcome of current diabetes therapies. This study aimed to investigate the association between TIR and the severity of the urinary albumin excretion rate (UAER) in patients with type 2 diabetes mellitus (T2DM). Methods: We retrospectively analyzed the data of 1014 inpatients with T2DM at the Department of Endocrinology and Metabolism of Peking University International Hospital, China. TIR was defined as the percentage of blood glucose within the target range of 3.90-10.00 mmol/L. Urine samples for assessment of UAER were collected for 3 consecutive days from the start of hospitalization. Results: The TIR values for patients with normal urine levels of albumin, microalbuminuria, and macroalbuminuria were 70% +/- 20%, 50% +/- 20%, and 30% +/- 20%, respectively (all P < 0.001). The patients were stratified according to quartiles of TIR as follows: quartile (Q) 1, <55%; Q2, 55%-72%; Q3, 73%-83%; and Q4, >83%. The incidences of microalbuminuria in Q1, Q2, Q3, and Q4 were 41.1%, 21.6%, 7.1%, and 5.5% (all P < 0.001), respectively. The respective incidences of macroalbuminuria were 24.2%, 1.1%, 1.4%, and 0% (all P < 0.001). In multinomial logistic regression analyses, TIR was significantly correlated with microalbuminuria (odds ratio [OR] 0.58, 95% confidence interval [CI]: 0.52-0.65, P < 0.001) and macroalbuminuria (OR 0.26, 95% CI: 0.18-0.38, P < 0.001) after adjusting for age, sex, body mass index, diabetes duration, systolic blood pressure, and levels of triglycerides, glycosylated hemoglobin A1c, and creatinine. Conclusion: The proportion of blood glucose in TIR is closely related to the severity of UAER in patients with T2DM.
引用
收藏
页码:1052 / 1056
页数:5
相关论文
共 24 条
  • [1] Positioning time in range in diabetes management
    Advani, Andrew
    [J]. DIABETOLOGIA, 2020, 63 (02) : 242 - 252
  • [2] Clinical Manifestations of Kidney Disease Among US Adults With Diabetes, 1988-2014
    Afkarian, Maryam
    Zelnick, Leila R.
    Hall, Yoshio N.
    Heagerty, Patrick J.
    Tuttle, Katherine
    Weiss, Noel S.
    de Boer, Ian H.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2016, 316 (06): : 602 - 610
  • [3] Kidney Disease and Increased Mortality Risk in Type 2 Diabetes
    Afkarian, Maryam
    Sachs, Michael C.
    Kestenbaum, Bryan
    Hirsch, Irl B.
    Tuttle, Katherine R.
    Hinnmelfarb, Jonathan
    de Boer, Ian H.
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2013, 24 (02): : 302 - 308
  • [4] Standardizing Clinically Meaningful Outcome Measures Beyond HbA1c for Type 1 Diabetes: A Consensus Report of the American Association of Clinical Endocrinologists, the American Association of Diabetes Educators, the American Diabetes Association, the Endocrine Society, JDRF International, The Leona M. and Harry B. Helmsley Charitable Trust, the Pediatric Endocrine Society, and the T1D Exchange
    Agiostratidou, Gina
    Anhalt, Henry
    Ball, Dana
    Blonde, Lawrence
    Gourgari, Evgenia
    Harriman, Karen N.
    Kowalski, Aaron J.
    Madden, Paul
    McAuliffe-Fogarty, Alicia H.
    McElwee-Malloy, Molly
    Peters, Anne
    Raman, Sripriya
    Reifschneider, Kent
    Rubin, Karen
    Weinzimer, Stuart A.
    [J]. DIABETES CARE, 2017, 40 (12) : 1622 - 1630
  • [5] Alberti KGMM, 1998, DIABETIC MED, V15, P539, DOI 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO
  • [6] 2-S
  • [7] Chronic kidney disease in US adults with type 2 diabetes: An updated national estimate of prevalence based on Kidney Disease: Improving Global Outcomes (KDIGO) staging
    Bailey R.A.
    Wang Y.
    Zhu V.
    Rupnow M.F.
    [J]. BMC Research Notes, 7 (1)
  • [8] Validation of Time in Range as an Outcome Measure for Diabetes Clinical Trials
    Beck, Roy W.
    Bergenstal, Richard M.
    Riddlesworth, Tonya D.
    Kollman, Craig
    Li, Zhaomian
    Brown, Adam S.
    Close, Kelly L.
    [J]. DIABETES CARE, 2019, 42 (03) : 400 - 405
  • [9] The Fallacy of Average: How Using HbA1c Alone to Assess Glycemic Control Can Be Misleading
    Beck, Roy W.
    Connor, Crystal G.
    Mullen, Deborah M.
    Wesley, David M.
    Bergenstal, Richard M.
    [J]. DIABETES CARE, 2017, 40 (08) : 994 - 999
  • [10] Comparison of Insulin Glargine 300 Units/mL and 100 Units/mL in Adults With Type 1 Diabetes: Continuous Glucose Monitoring Profiles and Variability Using Morning or Evening Injections
    Bergenstal, RichardM.
    Bailey, Timothy S.
    Rodbard, David
    Ziemen, Monika
    Guo, Hailing
    Muehlen-Bartmer, Isabel
    Ahmann, Andrew J.
    [J]. DIABETES CARE, 2017, 40 (04) : 554 - 560